William Blair Analysts Boost Earnings Estimates for Incyte

Incyte Co. (NASDAQ:INCY) – Stock analysts at William Blair raised their Q2 2025 earnings estimates for shares of Incyte in a research report issued to clients and investors on Tuesday, March 18th. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will post earnings of $1.11 per share for the quarter, up from their prior estimate of $1.10. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Incyte’s current full-year earnings is $4.86 per share. William Blair also issued estimates for Incyte’s Q3 2025 earnings at $1.19 EPS and Q3 2026 earnings at $1.30 EPS.

A number of other equities research analysts also recently issued reports on the stock. Stifel Nicolaus boosted their price objective on shares of Incyte from $75.00 to $77.00 and gave the company a “hold” rating in a research report on Monday, February 10th. UBS Group started coverage on shares of Incyte in a research note on Tuesday, December 17th. They set a “neutral” rating and a $77.00 target price on the stock. Truist Financial lowered their target price on shares of Incyte from $74.00 to $72.00 and set a “hold” rating on the stock in a research note on Tuesday. StockNews.com cut shares of Incyte from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 12th. Finally, Wells Fargo & Company lifted their target price on shares of Incyte from $68.00 to $70.00 and gave the company an “equal weight” rating in a research note on Thursday, December 19th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $75.13.

Incyte Trading Up 0.6 %

Shares of INCY stock opened at $60.34 on Thursday. Incyte has a 1 year low of $50.35 and a 1 year high of $83.95. The firm has a fifty day moving average price of $71.03 and a 200-day moving average price of $70.20. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.97 and a quick ratio of 1.94. The company has a market cap of $11.68 billion, a price-to-earnings ratio of 223.49, a PEG ratio of 0.41 and a beta of 0.76.

Incyte (NASDAQ:INCY) last posted its earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.48). Incyte had a return on equity of 0.05% and a net margin of 0.77%.

Hedge Funds Weigh In On Incyte

Several hedge funds have recently added to or reduced their stakes in INCY. California State Teachers Retirement System grew its stake in Incyte by 0.8% in the 4th quarter. California State Teachers Retirement System now owns 241,033 shares of the biopharmaceutical company’s stock worth $16,648,000 after acquiring an additional 1,833 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in Incyte by 315.2% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 47,884 shares of the biopharmaceutical company’s stock worth $3,307,000 after acquiring an additional 36,351 shares in the last quarter. NorthCrest Asset Manangement LLC grew its stake in Incyte by 22.6% in the 4th quarter. NorthCrest Asset Manangement LLC now owns 7,982 shares of the biopharmaceutical company’s stock worth $551,000 after acquiring an additional 1,470 shares in the last quarter. Lansforsakringar Fondforvaltning AB publ bought a new position in Incyte in the 4th quarter worth about $3,919,000. Finally, Siemens Fonds Invest GmbH bought a new position in Incyte in the 4th quarter worth about $401,000. 96.97% of the stock is currently owned by institutional investors.

Insider Activity

In related news, EVP Steven H. Stein sold 12,352 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $72.69, for a total transaction of $897,866.88. Following the transaction, the executive vice president now directly owns 66,967 shares in the company, valued at approximately $4,867,831.23. This represents a 15.57 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Barry P. Flannelly sold 19,807 shares of the company’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $67.69, for a total transaction of $1,340,735.83. Following the transaction, the executive vice president now owns 33,567 shares in the company, valued at $2,272,150.23. The trade was a 37.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 46,827 shares of company stock worth $3,322,618. 17.60% of the stock is currently owned by corporate insiders.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.